Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Grifols (GRFS) a Great Value Stock Right Now?

ABM Industries

Gevo

GEVO, GRFS and ABM have been added to the Zacks Rank #5 (Strong Sell) List on January 13, 2023.

New Strong Sell Stocks for January 13th (Revised)

New Strong Sell Stocks for January 13th

AlphaID™ At Home, the company's first FDA clearance for direct-to-consumer use, enables U.S. adults to screen for their genetic risk of alpha1-antitrypsin deficiency (alpha-1) without prescription from a healthcare professional A simple saliva sample collected at home will detect the chances of developing lung and/or liver disease linked to alpha-1, including chronic obstructive pulmonary disease (COPD), a group of respiratory illnesses During November, awareness month for both alpha-1 and COPD, Grifols underscores its longtime commitment to the alpha-1 community and identifying more COPD patients with alpha-1 BARCELONA, Spain , Nov. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).  The service, also known as AlphaID™ At Home, is the company's first FDA clearance for direct-to-consumer use.

Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1

Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributions Steven F . Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.

Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.

GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens

The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving plasma-protein therapy Building on its investment in a large-scale fractionation facility in Montreal, Grifols will manufacture plasma sourced in Canada to provide finished product exclusively for Canadian Blood Services to help it reach at least 50% Ig self-sufficiency for Canadians Under a 15-year agreement with options to renew, an incremental 2.4 million grams of Ig will be provided annually for Canadian patients and Canadian Blood Services, with pricing in line with Western market values and subject to periodic reviews Once more Grifols demonstrates global leadership forging alliances between the plasma industry and the public sector as the best way to ensure domestic plasma self-sufficiency BARCELONA, Spain , Sept. 7, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.

Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “GMP manufacturing and IND-enabling studies of a recombinant hyperimmune globulin targeting SARS-CoV-2,” in the international, peer-reviewed journal Pathogens. This work showcases for the first time the GMP (good manufacturing practice) manufacturing and IND (Investigational New Drug)-enabling studies of its new class of drugs, recombinant polyclonal antibodies, describing the company's recombinant polyclonal product that targets SARS-CoV-2, GIGA-2050.

GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies

Banco de Chile

Amdocs

New Oriental Education & Technology Group

LTC Properties

According to model portfolio statistics, five stocks in the Historical Low Price-Sales Model Portfolio that have gained more than 6% in the year to date are Banco de Chile ( BCH , Financial), LTC Properties Inc. ( LTC , Financial), Amdocs Ltd. ( DOX , Financial), New Oriental Education & Technology Group Inc. ( EDU , Financial) and Grifols SA ( GRFS , Financial).

5 High-Performing Stocks in Historical Low PS Model Portfolio

Bayer AG

Takeda Pharmaceutical

These three healthcare stocks should hold their value for years.

Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development

BARCELONA, Spain, April 29, 2022 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 29, 2022.

Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022

- After obtaining all regulatory approvals, Grifols has closed the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, which owns 90% of the ordinary shares and 1% of the preferred shares of Biotest AG. - Having completed the Public Takeover Offer (PTO) and closed the acquisition of Tiancheng (Germany) Pharmaceutical Holdings, Grifols now controls 96.20% of the voting rights of Biotest AG and holds 69.72% of its share capital.

Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation

BARCELONA, Spain, March 2, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the health and well-being of people, today announced it is partnering with Feeding America, the nation's largest domestic hunger-relief organization, to help "box out hunger" by collecting nonperishable food and raising money for local member food banks across the country. Through the collaboration, Grifols employees, donors and community neighbors will team up with local businesses and community organizations throughout the month of March to help collect nonperishable food items for local Feeding America member food banks.

Grifols partners with Feeding America® to help address hunger in the U.S.

BARCELONA, Spain, Feb. 24, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of AT-III, a plasma protein that treats patients with blood clotting issues.

Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis

Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in.

Grifols: Short-Term Turbulence But Long-Term Upside

BARCELONA, Spain, Feb. 9, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced that its PharmacyKeeper Verification software has been named No. 1 Category Leader in IV Workflow Management in the 2022 Best in KLAS: Software and Services report for the sixth consecutive year.

Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS,' extends category leadership for sixth consecutive year

BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash.

Grifols acquires its first plasma donation center in Canada

BARCELONA, Spain, Nov. 30, 2021 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies, today announced the opening of its 300th plasma donor center in the U.S., the company's first-ever donation center in the state of Massachusetts and second in New England. Located in the VA Building at the UMass Chan Medical School campus in Worcester, Mass.

Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma

BARCELONA, Spain, Nov. 4, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations.

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

BARCELONA, Spain, Oct. 19, 2021 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, and the National Service Projects Organization (NSPO) in Egypt today inaugurated the first integrated plasma-supply platform in Africa, the start of a robust plasma infrastructure that will bring self-sufficiency to Egypt while facilitating access to plasma products for the broader Middle East and African region, as well as other countries.     Innovative in its goals and scope, the alliance that Grifols and Egypt announced in November 2020 is the first ever that pairs a government entity and a private plasma manufacturer to tackle national self-sufficiency.

Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines

Spanish pharmaceutical company Grifols SA said Friday that it has reached an agreement to acquire a majority stake in German peer Biotest AG.

Pharma deal: Biotest up 12% after Grifols to pay $1.3 billion for majority stake

Spain-based biotech Grifols SA ( GRFS , Financial) is trading low due to the effects of the pandemic on sales and revenue. The company is completely vertically integrated in the plasma business.

Grifols Sells Off With Effects of Pandemic

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Grifols (GRFS)

Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook.

News for Grifols, S.A. Stock (GRFS)